New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...
Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.
PRNewswire/ -- (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today ...
A recent breakthrough in medical research offers exciting possibilities for people dealing with diabetes and obesity. This ...
The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...
Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...
Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...
Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...